Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2007

View Archived Issues

New p38 MAPK inhibitors emerge from Ono R&D

Clinical trials of omalizumab therapy for asthma

Novel antiinfective agents disclosed in recent patent literature

Tanabe Seiyaku reviews domestic and overseas developments of past year

Desmoteplase fails to meet primary endpoint in acute ischemic stroke

Ecabet sodium demonstrates improvements in dry eye syndrome

Patent protection for administration of ChronVac-C by electroporation

Iroxanadine accelerates wound healing in diabetic animals

Positive preclinical findings reported for Scavidin

HalcyGen to develop antiinfectives licensed from Mayne Pharma

Medarex and Mitsubishi collaborate in autoimmune disease

New biomarkers point to Alzheimer's disease-linked inflammation in the brain

Peregrine enters development collaboration with Dios Therapeutics

Allos studies PDX and gemcitabine in NHL and Hodgkin's disease patients

Second approvable letter for Labopharm's once-daily tramadol

Phase III trial of Delcath System approved to expand into multiple sites

Neuro-Hitech obtains license to drug combinations for neuronal dysfunction

ThermoDox completes phase I study in nonresectable liver cancer

Transdermal low-dose contraceptive begins phase I pharmacokinetic program

Positive interim phase I findings for inhaled alpha-1 antitrypsin

Subcutaneous methylnaltrexone NDA accepted for review

Abbott seeks FDA approval of Xience V stent

Interim phase I results reported at ASCO for INNO-406, a dual Bcr-Abl/Lyn kinase inhibitor

Good safety demonstrated for a new antisense inhibitor of Akt-1

Investigators announce final results of phase II trial of anti-EpCAM antibody

Phase II dose and schedule of R-547 selected based on phase I data

AMG-655 shows good safety and evidence of activity in advanced cancer

Orally active PARP inhibitor proves safe and effective in ovarian cancer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026